BVF Inc. IL cut its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,356,782 shares of the company’s stock after selling 618,131 shares during the period. Revolution Medicines makes up 9.0% of BVF Inc. IL’s portfolio, making the stock its 2nd largest holding. BVF Inc. IL’s holdings in Revolution Medicines were worth $267,368,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the business. Caligan Partners LP grew its position in Revolution Medicines by 20.6% in the 4th quarter. Caligan Partners LP now owns 1,283,900 shares of the company’s stock valued at $102,263,000 after acquiring an additional 219,651 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Revolution Medicines by 4.3% during the fourth quarter. ADAR1 Capital Management LLC now owns 145,079 shares of the company’s stock valued at $11,556,000 after purchasing an additional 5,943 shares during the period. AQR Capital Management LLC boosted its stake in shares of Revolution Medicines by 80.9% during the fourth quarter. AQR Capital Management LLC now owns 127,170 shares of the company’s stock valued at $10,129,000 after purchasing an additional 56,881 shares during the period. Abel Hall LLC purchased a new stake in shares of Revolution Medicines during the fourth quarter valued at $439,000. Finally, MPM Bioimpact LLC boosted its stake in shares of Revolution Medicines by 60.2% during the fourth quarter. MPM Bioimpact LLC now owns 505,672 shares of the company’s stock valued at $40,277,000 after purchasing an additional 189,950 shares during the period. Institutional investors own 94.34% of the company’s stock.
Insider Activity at Revolution Medicines
In related news, insider Mark A. Goldsmith sold 120,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the transaction, the insider directly owned 276,698 shares of the company’s stock, valued at $41,529,602.82. This trade represents a 30.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Margaret A. Horn sold 60,400 shares of Revolution Medicines stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the transaction, the chief operating officer directly owned 158,222 shares in the company, valued at approximately $25,342,417.74. The trade was a 27.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 210,000 shares of company stock worth $32,424,620. 7.60% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
View Our Latest Report on Revolution Medicines
Revolution Medicines Trading Up 0.8%
Shares of NASDAQ RVMD opened at $157.77 on Thursday. The firm has a market cap of $33.54 billion, a PE ratio of -22.32 and a beta of 1.40. The business has a fifty day simple moving average of $144.38 and a two-hundred day simple moving average of $112.39. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $166.50.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the firm earned ($1.13) EPS. Analysts expect that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.
Revolution Medicines Company Profile
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Featured Stories
- Five stocks we like better than Revolution Medicines
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
